This study aimed to establish serum reference ranges for the Lumipulse G NfL Blood assay <CE>, supporting its clinical utility and regulatory validation. The assay is intended to detect NfL as a biomarker of neuro-axonal damage irrespective of the cause and can contribute to the monitoring of disease activity in patients with neurological diseases.